Researchers have identified prognostic factors associated with cardiovascular (CV) and non-CV mortality in elderly patients with chronic heart failure (CHF), and are calling for preventive measures to begin as early as the age of 65 years in patients with CHF.
Most patients on the angiotensin receptor-neprilysin inhibitor (ARNI) sacubitril/valsartan are started on the lowest dose and remain on the lowest or intermediate dose of the drug, data from primary care and cardiology practices in Germany have shown.
Cost, concerns over a lack of long-term clinical data, and injection fear were the top reasons cited for nonadherence to evolocumab therapy, according to a small study assessing the real-world barriers among patients with coronary artery disease (CAD).
Although higher levels of HDL-cholesterol (HDL-C) are associated with reduced cardiovascular disease (CVD) risk, the relationship is not linear and after an intermediate range of 50–70 mg/dL, very high HDL-C is not always associated with lower CV risk.
In patients with heart failure with reduced ejection fraction (HFrEF), switch of therapy from an angiotensin-converting enzyme inhibitor (ACEI) to the angiotensin receptor-neprilysin inhibitor (ARNI) sacubitril/valsartan significantly improves left ventricular ejection fraction (LVEF) at 1 year.
A meta-analysis of 1,526 patients showed that proprotein convertase subtilisin–kexin type 9 (PCSK9) inhibitors are safe and effective compared with placebo at reducing LDL-cholesterol (LDL-C) in patients with familial hypercholesterolaemia (FH).
A new batch of apolipoprotein B (apoB)-lowering drugs that capitalize on statins’ ability to lower lipids will further benefit patients at high cardiovascular (CV) risk who need to be treated more aggressively.
Chronic pancreatitis patients taking antioxidants (AO) supplementation show a sustained increase in blood levels of AO, but no additional benefit is seen on endocrine and exocrine functions, markers of fibrosis, oxidative stress (OS) and inflammation, nutritional status, pain, and quality of life (QOL) when compared with those on placebo, according to a study.
Pneumonia is a common infection– affecting around 3,200 people inSingapore in 2016 – making it the thirdmost common cause of hospitalisation inthe country. Its common complications,especially with delayed or inappropriatetreatment, include bacteraemia andseptic shock, lung abscesses, pleuraleffusions, empyema, pleurisy, respiratoryfailure and renal failure.